（编辑 袁冠琳） 证券日报网讯 中广核技8月4日在互动平台回答投资者提问时表示，公司积极应对市场竞争，依托"非动 力核技术应用"产业背景，加快新材料产品转型升级节奏，通过强化经营管理、加大市场开发、加速调 整产品结构、推进新产品研发、提升高毛利产品占比等多项措施，提升整体盈利能力和水平。 ...

Core Viewpoint - The proton medical business of China General Nuclear Power Technology Development Co., Ltd. (CGN Tech) has received support from its controlling shareholder, which is expected to facilitate the development of this business segment [2][4]. Group 1: Investment and Financial Support - The controlling shareholder, China General Nuclear Technology Application Co., Ltd., plans to inject 500 million yuan into CGN Tech's wholly-owned subsidiary, CGN Medical Technology (Mianyang) Co., Ltd., to support the research and development of proton medical projects [2]. - After the capital increase, the controlling shareholder will hold 44.13% of the shares in Mianyang Medical, while CGN Tech's shareholding will decrease to 55.87%, transforming Mianyang Medical from a wholly-owned subsidiary to a controlled subsidiary [4]. Group 2: Business Development and Market Potential - CGN Tech's medical health business began in 2020, focusing on the introduction of multi-room proton therapy technology from Belgium's IBA and establishing a manufacturing base for proton medical equipment in Mianyang, Sichuan [2]. - Proton therapy is recognized for its high precision, low side effects, and shorter treatment duration, making it increasingly popular among doctors and patients [3]. - The company has made significant progress in its proton medical business, including the development of a compact proton therapy system with independent intellectual property rights and the completion of its proton industry park, which has commenced production [3][4]. Group 3: Industry Insights - The demand for proton medical equipment is expected to grow due to increasing health awareness and advancements in medical technology, indicating a broad development space for this sector [3]. - The cash injection from the controlling shareholder is anticipated to alleviate financial pressure on CGN Tech and enhance its core competitiveness in the medical health business [5].